- Dr. Franco has a long-standing interest in epigenetics, gene regulation and non-coding RNAs, particularly how it pertains to cancer. His research program uses genomic, proteomic and molecular approaches to study how endocrine signaling and inflammatory signaling exacerbate hormone-dependent cancers. In addition, Dr. Franco's studies focus on understanding how regulatory information is encoded in the human genome and how genes become deregulated in cancer.
- Interplay between inflammatory and estrogen signaling in breast cancer.
- Nagari A, Franco HL Cytokine 2015 Dec 76 2 588-90
- No driver behind the wheel? Targeting transcription in cancer.
- Franco HL, Kraus WL Cell 2015 Sep 163 1 28-30
- TNFa signaling exposes latent estrogen receptor binding sites to alter the breast cancer cell transcriptome.
- Franco HL, Nagari A, Kraus WL Mol. Cell 2015 Apr 58 1 21-34
- Nonsense mutations of the bHLH transcription factor TWIST2 found in Setleis Syndrome patients cause dysregulation of periostin.
- Franco HL, Casasnovas JJ, Leon RG, Friesel R, Ge Y, Desnick RJ, Cadilla CL Int. J. Biochem. Cell Biol. 2011 Oct 43 10 1523-31
- Redundant or separate entities?--roles of Twist1 and Twist2 as molecular switches during gene transcription.
- Franco HL, Casasnovas J, Rodríguez-Medina JR, Cadilla CL Nucleic Acids Res. 2011 Mar 39 4 1177-86
- Homozygous nonsense mutations in TWIST2 cause Setleis syndrome.
- Tukel T, Šošic D, Al-Gazali LI, Erazo M, Casasnovas J, Franco HL, Richardson JA, Olson EN, Cadilla CL, Desnick RJ Am. J. Hum. Genet. 2010 Aug 87 2 289-96
Honors & Awards
- K99/R00 National Cancer Institute Pathway to Independence Award
Mechanisms of FoxA1 Latent Enhancer Formation in Response to Proinflammatory Signaling in Hormone Dependent Cancers (2016-2021)
- American Cancer Society Postdoctoral Fellowship
Expression and Function of Novel Long Non-Coding RNAs in Breast Cancer (2013-2016)
- NIH / NIDDK Postdoctoral Support Award for Minorities in Science
Activity of Nuclear Receptor Coregulators with Chromatin (2012-2013)